Browsing Tag:Taxpayer

alzheimers-drug-is-bonanza-for-biogen-most-likely-at-taxpayer-expense
In addition to the US, Biogen has also asked regulators in Australia, Brazil, Canada, the European Union, Japan, and Switzerland to review the drug.US approval is a critical win for a company that has relied on Aduhelm to offset stalled or declining sales of its other products. Competitors introduced generics of Biogen's multiple sclerosis drug Tecfidera last year,...
Continue reading
0 Comments
Share